Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - alanine; arginine ; glycine; histidine; isoleucine; leucine ; lysine acetate; methionine; phenylalanine; proline; serine; taurine; threonine; tryptophan; tyrosine; valine; calcium chloride dihydrate; sodium glycerophosphate; magnesium sulfate; potassium chloride; sodium acetate trihydrate ; zinc sulphate heptahydrate; glucose monohydrate; soya-bean oil refined; triglycerides medium-chain ; olive oil, refined; fish oil, rich in omega-3 acids - emulsion for infusion - combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cabazitaxel - concentrate for solution for infusion - cabazitaxel

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - lacosamide - solution for infusion - lacosamide

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - thiotepa - powder for concentrate for solution for infusion - thiotepa

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - thiotepa - powder for concentrate for solution for infusion - thiotepa

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - anidulafungin - powder for concentrate for solution for infusion - 100 milligram(s) - other antimycotics for systemic use; anidulafungin

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - multiple myeloma - antineoplastic agents - bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - propofol - emulsion for injection/infusion - 20 milligram(s)/millilitre - other general anesthetics; propofol

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - propofol - emulsion for injection/infusion - 20 milligram(s)/millilitre - other general anesthetics; propofol

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - breast cancerdocetaxel kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small-cell lung cancerdocetaxel kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.docetaxel kabi in combination with androgen-deprivation therapy (adt), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.gastric adenocarcinomadocetaxel kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.